Navigation Links
ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
Date:9/19/2007

WINDSOR, Ontario, Sept. 19 /PRNewswire/ -- ArtJen Complexus Holdings Corp. (http://www.fbcx.com) today announced that, following the results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is being studied by a major US west-coast university medical center. The largest study to date on the patented all- natural soluble fiber that binds dietary fat will involve overweight but not obese individuals.

"Our earlier study with obese, type 2 diabetics demonstrated significant weight loss when adjusted for changes in diet." said FBCx co-inventor, Dr. Catherine Jen. "It's time to look at the non-obese population segment that would benefit from losing 10-25 pounds."

"We expect this study will show FBCx to be an easy and effective aid for losing weight and for lowering elevated levels of blood fats," continued FBCx co-inventor, Dr. Joseph Artiss.

Previous FBCx study findings include:

-- Effective at reducing and/or maintaining body weight in patients with

type 2 diabetes.

-- Lowered both triglyceride and LDL (bad) cholesterol levels in patients

who began the study with elevated triglyceride levels.

-- Blood work findings indicate an insulin sensitivity increase and

therefore a possible delay in the need to institute or the intensity of

insulin therapy in type 2 diabetics.

-- FBCx was shown to bind and remove 9 times its own weight in dietary

fat, essentially preventing 80 calories from being absorbed per tablet.

-- FBCx appears to preferentially bind saturated over unsaturated dietary

fats.

-- FBCx produced no adverse side effects.

These findings and others have lead to FBCx being referred to as the "miracle weight loss" pill in media reports and by renowned members of the medical profession.

"We are so convinced of the efficacy of FBCx that we sought out and funded this major study ourselves," said Dr. Artiss.

"I have spent my entire career studying obesity. FBCx works where most others have failed to live up to their hype," stated Dr. Jen.

FBCx co-inventors are Associate Professor of Pathology Joseph Artiss, Ph.D., FACB and K-L Catherine Jen, Ph.D., Professor and Chair of Nutrition and Food Science, both of Wayne State University in Detroit, Michigan.

Six tablets daily are capable of removing 50-60% of the calories from a typical North American diet.


'/>"/>
SOURCE ArtJen Complexus Holdings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
(Date:3/24/2017)... March 24, 2017 Today Stock-Callers.com have ... which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), ... SSH ). These companies are part of the ... on Thursday, March 23 rd , 2017, with the NYSE ... of health care companies in the S&P 500 were down ...
Breaking Medicine Technology:
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA ... does not obey the rules Congress has directed the CBO to follow. The CBO ... reform would restore. Yet, it estimates a reduction in employer-based coverage due to the ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... Westchester County, NY (PRWEB) , ... March 24, 2017 , ... ... in Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. ... as a law clerk for the firm, will concentrate her practice in elder law, ...
Breaking Medicine News(10 mins):